EIF2AK3 and neoplasm: In support of the hypothesis that PAM activation in tumors is PERK-dependent, it was demonstrated that the use of GSK2606414 suppressed PAM activity, whereas the PERK agonist CCT020312 intensified PAM cleavage, triggering cytosolic signaling of the fragment that fosters tumor migration and angiogenesis [64].